Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Showcases Groundbreaking Body of Research at the 2018 Annual Meeting of the American Association for Cancer Research
More than 50 abstracts highlight the diverse capabilities of NanoString’s technology from gene expression profiling to Digital Spatial Profiling SEATTLE , April 12, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and
View HTML
Toggle Summary NanoString Announces Launch of Breast Cancer 360 Research Panel, Expanding the 360 Series of Cancer Panels for Translational Research and Signature Development
SEATTLE , April 10, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of the Breast Cancer 360™ (BC 360) research panel.
View HTML
Toggle Summary NanoString to Release First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018
SEATTLE , April 09, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2018 financial results after the close of trading on
View HTML
Toggle Summary NanoString Technologies Releases Fourth Quarter and Full Year 2017 Operating Results and Provides 2018 Outlook
SEATTLE , March 07, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the fourth quarter and year ended December 31, 2017.
View HTML
Toggle Summary NanoString to Present at the 38th Annual Cowen Healthcare Conference
SEATTLE , March 06, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the 38th Annual Cowen Healthcare
View HTML
Toggle Summary NanoString Technologies to Release Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call on Wednesday, March 7, 2018
SEATTLE , Feb. 21, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter and fiscal year 2017 financial results after the close
View HTML
Toggle Summary NanoString Showcases Groundbreaking New Platforms at 2018 Advances in Genome Biology and Technology (AGBT) Conference
Digital Spatial Profiling Demonstrates Profiling of Proteins and 1,000+ mRNAs Across Multiple Regions from FFPE Tissue Sections using Next Generation Sequencing Readout First Customer Data Using Hyb & Seq Single Molecule Sequencing Demonstrates Potential Utility in Oncology and Infectious Disease
View HTML
Toggle Summary NanoString Announces Largest and Most Comprehensive Study to Date of Prosigna Breast Cancer Assay Published in Journal of Clinical Oncology
Comprehensive Study Includes All Danish Women Diagnosed with Breast Cancer from 2000 to 2003 who were Indicated for Prosigna and Treated with Endocrine Therapy Accompanying Editorial Highlights Encouraging Data on Clinical Utility in Node-Positive Breast Cancer SEATTLE , Feb.
View HTML
Toggle Summary NanoString Reports Inducement Grant Under NASDAQ Listing Rules
SEATTLE , Jan. 19, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Thomas Bailey , NanoString's
View HTML
Toggle Summary NanoString Appoints Thomas Bailey as Chief Financial Officer
SEATTLE , Jan. 16, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Thomas Bailey has been appointed chief financial officer, effective January 16, 2018 .    Mr.
View HTML